The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.